BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Abstract KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRASG12C inhibitors is limited by intrinsi...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2022-03-01
Serie:	Journal of Hematology & Oncology
Ämnen:	KRASG12C BCL-XL PROTAC Sotorasib Drug resistance
Länkar:	https://doi.org/10.1186/s13045-022-01241-3
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!